Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer.

Unlabelled: The utility of breast magnetic resonance imaging in patients receiving neoadjuvant chemotherapy is not well defined. We compared serial magnetic resonance imaging examinations with histologic posttreatment examinations in patients treated with primary chemotherapy for locally advanced br...

Full description

Bibliographic Details
Published in:Cancer Journal Vol. 12; no. 3; pp. 212 - 222
Main Authors: Kwong MS, Chung GG, Horvath LJ, Ward BA, Hsu AD, Carter D, Tavassoli F, Haffty B, Burtness BA, Kwong, Myron S, Chung, Gina G, Horvath, Laura J, Ward, Barbara A, Hsu, Arlene D, Carter, Darryl, Tavassoli, Fatteneh, Haffty, Bruce, Burtness, Barbara A
Format: research Journal Article
Published: Lippincott Williams & Wilkins May/Jun2006
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106199928&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106199928
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        15289117
        4U5
      jtl: Cancer Journal
      issn: 15289117
      maglogo: N
    pubinfo:
      dt: May/Jun2006
      vid: 12
      iid: 3
      pid: 5086
      pub: Lippincott Williams & Wilkins
      place: Baltimore, Maryland
    artinfo:
      ui:
        106199928
        NLM16803680
        2009208316
        10.1097/00130404-200605000-00010
        NLM16803680
        106199928
      ppf: 212
      ppct: 10
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer.
      aug:
        au:
          Kwong MS
          Chung GG
          Horvath LJ
          Ward BA
          Hsu AD
          Carter D
          Tavassoli F
          Haffty B
          Burtness BA
          Kwong, Myron S
          Chung, Gina G
          Horvath, Laura J
          Ward, Barbara A
          Hsu, Arlene D
          Carter, Darryl
          Tavassoli, Fatteneh
          Haffty, Bruce
          Burtness, Barbara A
        affil: Section of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
      sug:
        subj:
          Antineoplastic Agents, Combined Therapeutic Use
          Breast Neoplasms Diagnosis
          Breast Neoplasms Drug Therapy
          Magnetic Resonance Imaging Methods
          Adult
          Chemotherapy, Adjuvant
          Doxorubicin Administration and Dosage
          Female
          Granulocyte Colony-Stimulating Factor Administration and Dosage
          Hydrocarbons Administration and Dosage
          Mastectomy
          Middle Age
          Neoadjuvant Therapy
          Neoplasm Invasiveness
          Neoplastic Processes
          Prognosis
          Survival
          Treatment Outcomes
          Human
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Female
      ab: Unlabelled: The utility of breast magnetic resonance imaging in patients receiving neoadjuvant chemotherapy is not well defined. We compared serial magnetic resonance imaging examinations with histologic posttreatment examinations in patients treated with primary chemotherapy for locally advanced breast cancer.Patients and Methods: Eligible patients with locally advanced breast cancer received doxorubicin 60 mg/m(2) and docetaxel 60 mg/m(2) (with granulocyte colony stimulating factor support) every 14 days for a maximum of six cycles. Breast magnetic resonance imaging was performed at baseline and repeated every two cycles. Surgery (either local excision or mastectomy) was performed after six cycles in responding or stable patients. Residual tumor size on pathology and preoperative magnetic resonance imaging was compared; concordance was defined as a < or = 0.5-cm difference.Results: To date, three of 17 enrolled subjects (17.6%) attained pathologic complete response, and three additional patients attained near pathologic complete response, with residual foci of < or = 1 mm. Of these six patients, only one was disease-free by magnetic resonance imaging. Discordance between magnetic resonance imaging findings and pathologic evaluation was found in four of six patients (66.6%) who obtained pathologic complete response or near pathologic complete response. In the three patients in whom four axillary lesions were followed with magnetic resonance imaging, discordance was found in all four lesions, with magnetic resonance imaging overestimating pathologic disease in all cases.Discussion: Our findings caution that magnetic resonance imaging may frequently overestimate residual invasive carcinoma after neoadjuvant chemotherapy. These results contradict previous studies suggesting that postchemotherapy magnetic resonance imaging may underestimate residual cancer. The use of magnetic resonance imaging in evaluating response to therapy in locally advanced breast cancer should be further studied.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N